Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis

Archives of Ophthalmology

Volumn 125, Issue 6, 2007, Pages 789-793

  Lalitha, Prajna ^a   Shapiro, Brett L ^b,c   Srinivasan, Muthiah ^a   Prajna, Namperumalsamy Venkatesh ^a   Acharya, Nisha R ^b,c   Fothergill, Annette W ^d   Ruiz, Jazmin ^d   Chidambaram, Jaya D ^c   Maxey, Kathryn J ^c   Hong, Kevin C ^c   McLeod, Stephen D ^b,c   Lietman, Thomas M ^b,c  

^a ARAVIND EYE HOSPITAL   (India)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d University of Texas Health Science Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ITRACONAZOLE; NATAMYCIN; POSACONAZOLE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS; CONTROLLED STUDY; DRUG EFFICACY; FUNGUS ISOLATION; FUSARIUM; KERATOMYCOSIS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; ULCER;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; ASPERGILLUS; CORNEAL ULCER; EYE INFECTIONS, FUNGAL; FUSARIUM; HUMANS; ITRACONAZOLE; MICROBIAL SENSITIVITY TESTS; NATAMYCIN; PEPTIDES, CYCLIC; PROSPECTIVE STUDIES; PYRIMIDINES; TRIAZOLES;

EID: 34250310860     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.6.789     Document Type: Article

References (43)

1. Xie L, Dong X, Shi W. Treatment of fungal keratitis by penetrating keratoplasty. Br J Ophthalmol. 2001;85:1070-1074.
2. Rosa RH Jr, Miller D, Alfonso EC. The changing spectrum of fungal keratitis in south Florida. Ophthalmology. 1994;101:1005-1013.
3. Whitcher JP, Srinivasan M. Corneal ulceration in the developing world - a silent epidemic. Br J Ophthalmol. 1997;81:622-623.
4. Thylefors B. Epidemiological patterns of ocular trauma. Aust N Z J Ophthalmol. 1992;20:95-98.
5. Srinivasan M. Fungal keratitis. Curr Opin Ophthalmol. 2004;15:321-327.
6. Nulens E, Eggink C, Rijs AJ, Wesseling P, Verweij PE. Keratitis caused by Scedosporium apiospermum successfully treated with a cornea transplant and voriconazole. J Clin Microbiol. 2003;41:2261-2264.
7. Lai TF, Malhotra R, Esmail-Zaden R, Galanopoulas A, Chehade M, Selva D. Use of voriconazole in Scedosporium apiospermum keratitis. Cornea. 2003;22:391, discussion 391-392.
8. Hernández Prats C, Llinares Tello F, Burgos San Jose A, Selva Otaolaurruchi J, Ordovas Baines JP. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother. 2004;38:414-417.
9. Sponsel W, Chen N, Dang D, et al. Topical voriconazole as a novel treatment for fungal keratitis. Antimicrob Agents Chemother. 2006;50:262-268.
10. Goldblum D, Frueh BE, Sarra GM, Katsoulis K, Zimmerli S. Topical caspofungin for treatment of keratitis caused by Candida albicans in a rabbit model. Antimicrob Agents Chemother. 2005;49:1359-1363.
11. Fitzsimons R, Peters AL. Miconazole and ketoconazole as a satisfactory first-line treatment for keratomycosis. Am J Ophthalmol. 1986;101:605-608.
12. Thomas PA. Current perspectives on ophthalmic mycoses. Clin Microbiol Rev. 2003;16:730-797.
13. Prajna NV, John RK, Nirmalan PK, Lalitha P, Srinivasan M. A randomised clinical trial comparing 2% econazole and 5% natamycin for the treatment of fungal keratitis. Br J Ophthalmol. 2003;87:1235-1237.
14. Rex JH, Pfaller MA. Has antifungal susceptibility testing come of age? Clin Infect Dis. 2002;35:982-989.
15. Greenwood D. In vitro veritas? antimicrobial susceptibility tests and their clinical relevance. J Infect Dis. 1981;144:380-385.
16. Wilhelmus KR, Abshire RL, Schlech BA. Influence of fluoroquinolone susceptibility on the therapeutic response of fluoroquinolone-treated bacterial keratitis. Arch Ophthalmol. 2003;121:1229-1233.
17. Alfonso E, Rosa RHJ. Fungal keratitis. In: Krachmer JH, Mannis MJ, Holland EJ, eds. Cornea. St Louis, Mo: Mosby; 1997.
18. Linares MJ, Charriel G, Solis F, Rodriguez F, Ibarra A, Casal M. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol. 2005;43:250-253.
19. Marangon FB, Miller D, Giaconi JA, Alfonso EC. In vitro investigation of voriconazole susceptibility for keratitis and endophthalmitis fungal pathogens. Am J Ophthalmol. 2004;137:820-825.
20. Bartlett JG, Auwaerter PG, Pham PA, eds The ABX Guide. Diagnosis & Treatment of Infectious Diseases. Montvale, NJ: Thomson PDR; 2005.
21. Moraes EM, Primola NS, Hamdan JS. Antifungal susceptibility of clinical and environmental isolates of Cryptococcus neoformans to four antifungal drugs determined by two techniques. Mycoses. 2003;46:164-168.
22. Moore CB, Walls CM, Denning DW. Comparison of three methods for in vitro susceptibility testing of Candida species with flucytosine. J Antimicrob Chemother. 2003;51:297-304.
23. González GM, Fothergill AW, Sutton DA, Rinaldi MG, Loebenberg D. In vitro activities of new and established triazoles against opportunistic filamentous and dimorphic fungi. Med Mycol. 2005;43:281-284.
24. Perea S, Fothergill AW, Sutton DA, Rinaldi MG. Comparison of in vitro activities of voriconazole and five established antifungal agents against different species of dermatophytes using a broth macrodilution method. J Clin Microbiol. 2001;39:385-388.
25. Kirkpatrick WR, McAtee RK, Revankar SG, et al. Comparative evaluation of National Committee for Clinical Laboratory Standards broth macrodilution and agar dilution screening methods for testing fluconazole susceptibility of Cryptococcus neoformans. J Clin Microbiol. 1998;36:1330-1332.
26. Patterson TF, Kirkpatrick WR, Revankar SG, et al. Comparative evaluation of macrodilution and chromogenic agar screening for determining fluconazole susceptibility of Candida albicans. J Clin Microbiol. 1996;34:3237-3239.
27. To WK, Fothergill AW, Rinaldi MG. Comparative evaluation of macrodilution and alamar colorimetric microdilution broth methods for antifungal susceptibility testing of yeast isolates. J Clin Microbiol. 1995;33:2660-2664.
28. Espinel-Ingroff A, Fothergill A, Ghannoum M, et al. Quality control and reference guidelines for CLSI broth microdilution susceptibility method (M 38-A document) for amphotericin B, itraconazole, posaconazole, and voriconazole. J Clin Microbiol. 2005;43:5243-5246.
29. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard. NCCLS document M38-A. Wayne, Pa: Clinical and Laboratory Standards Institute; 2002.
30. NCCLS. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts; Approved Standard. NCCLS document M27-A2. Wayne, Pa: Clinical and Laboratory Standards Institute; 2002.
31. Espinel-Ingroff A, Dawson K, Pfaller M, et al. Comparative and collaborative evaluation of standardization of antifungal susceptibility testing for filamentous fungi. Antimicrob Agents Chemother. 1995;39:314-319.
32. Espinel-Ingroff A, Bartlett M, Bowden R, et al. Multicenter evaluation of proposed standardized procedure for antifungal susceptibility testing of filamentous fungi. J Clin Microbiol. 1997;35:139-143.
33. Espinel-Ingroff A, Bartlett M, Chaturvedi V, et al. Optimal susceptibility testing conditions for detection of azole resistance in Aspergillus spp: NCCLS collaborative evaluation. National Committee for Clinical Laboratory Standards. Antimicrob Agents Chemother. 2001;45:1828-1835.
34. Kurtz MB, Heath IB, Marrinan J, Dreikorn S, Onishi J, Douglas C. Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase. Antimicrob Agents Chemother. 1994;38:1480-1489.
35. Agarwal PK, Roy P, Das A, Banerjee A, Maity P, Banerjee A. Efficacy of topical and systemic itraconazole as a broad-spectrum antifungal agent in mycotic corneal ulcer: a preliminary study. Indian J Ophthalmol. 2001;49:173-176.
36. Kalavathy CM, Parmar P, Kaliamurthy J, et al. Comparison of topical itraconazole 1% with topical natamycin 5% for the treatment of filamentous fungal keratitis. Cornea. 2005;24:449-452.
37. Arikan S, Lozano-Chiu M, Paetznick V, Nangia S, Rex JH. Microdilution susceptibility testing of amphotericin B, itraconazole, and voriconazole against clinical isolates of Aspergillus and Fusarium species. J Clin Microbiol. 1999;37:3946-3951.
38. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327-330.
39. Szekely A, Johnson EM, Warnock DW. Comparison of E-test and broth microdilution methods for antifungal drug susceptibility testing of molds. J Clin Microbiol. 1999;37:1480-1483.
40. Espinel-Ingroff A, Rezusta A. E-test method for testing susceptibilities of Aspergillus spp to the new triazoles voriconazole and posaconazole and to established antifungal agents: comparison with NCCLS broth microdilution method. J Clin Microbiol. 2002;40:2101-2107.
41. Johnson EM, Szekely A, Warnock DW. In-vitro activity of voriconazole, itraconazole and amphotericin B against filamentous fungi. J Antimicrob Chemother. 1998;42:741-745.
42. O'Day DM, Head WS, Robinson RD, Clanton JA. Corneal penetration of topical amphotericin B and natamycin. Curr Eye Res. 1986;5:877-882.
43. Clode AB, Davis JL, Salmon J, Michau TM, Gilger BC. Evaluation of concentration of voriconazole in aqueous humor after topical and oral administration in horses. Am J Vet Res. 2006;67:296-301.